- Home
- AVTX vs ICCM Comparison
AVTX vs ICCM Comparison
Compare AVTX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- ICCM
- Stock Information
- Founded
- AVTX 2011
- ICCM 2006
- Country
- AVTX United States
- ICCM Israel
- Employees
- AVTX N/A
- ICCM N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- AVTX Health Care
- ICCM
- Exchange
- AVTX Nasdaq
- ICCM Nasdaq
- Market Cap
- AVTX 88.4M
- ICCM 74.7M
- IPO Year
- AVTX 2015
- ICCM N/A
- Fundamental
- Price
- AVTX $8.46
- ICCM $1.11
- Analyst Decision
- AVTX Strong Buy
- ICCM Strong Buy
- Analyst Count
- AVTX 7
- ICCM 1
- Target Price
- AVTX $34.33
- ICCM $2.50
- AVG Volume (30 Days)
- AVTX 109.6K
- ICCM 352.8K
- Earning Date
- AVTX 05-12-2025
- ICCM 03-27-2025
- Dividend Yield
- AVTX N/A
- ICCM N/A
- EPS Growth
- AVTX N/A
- ICCM N/A
- EPS
- AVTX N/A
- ICCM N/A
- Revenue
- AVTX $441,000.00
- ICCM $3,291,000.00
- Revenue This Year
- AVTX N/A
- ICCM $75.63
- Revenue Next Year
- AVTX N/A
- ICCM $69.36
- P/E Ratio
- AVTX N/A
- ICCM N/A
- Revenue Growth
- AVTX N/A
- ICCM 1.92
- 52 Week Low
- AVTX $5.99
- ICCM $0.48
- 52 Week High
- AVTX $22.47
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- AVTX 56.89
- ICCM 35.03
- Support Level
- AVTX $7.88
- ICCM $1.04
- Resistance Level
- AVTX $9.00
- ICCM $1.25
- Average True Range (ATR)
- AVTX 0.81
- ICCM 0.09
- MACD
- AVTX 0.12
- ICCM -0.04
- Stochastic Oscillator
- AVTX 54.41
- ICCM 14.29
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.